Bioheart to acquire Pocket ECG manufacturer
Bioheart has entered into a non-binding letter of intent to acquire Medicalgorthmics, and the global rights to the Pocket ECG, a real-time, wireless heart monitor and diagnostic system, designed for long-term, automated electrocardiogram (ECG) arrhythmia analysis.
Under the terms of the non-binding letter of intent, both companies are expected to conduct their due diligence review within the next 60-90 days, according to the Sunrise, Fla.-based Bioheart. The terms of the agreement were not disclosed.
Pocket ECG connects to the patient via two or three electrodes and wirelessly transmits real time data 24-hours-per-day directly to the physician or a monitoring center so that long-term outpatient monitoring can be conducted over days or weeks, Bioheart said.
The device, manufactured by Medicalgorthmics in Austin, recently received CE mark approval for marketing throughout Europe.
Under the terms of the non-binding letter of intent, both companies are expected to conduct their due diligence review within the next 60-90 days, according to the Sunrise, Fla.-based Bioheart. The terms of the agreement were not disclosed.
Pocket ECG connects to the patient via two or three electrodes and wirelessly transmits real time data 24-hours-per-day directly to the physician or a monitoring center so that long-term outpatient monitoring can be conducted over days or weeks, Bioheart said.
The device, manufactured by Medicalgorthmics in Austin, recently received CE mark approval for marketing throughout Europe.